A Suárez-González1, S J Crutch2, F Roldán Lora3, E Franco-Macías4, E Gil-Néciga4. 1. Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, University College London, London, United Kingdom; Memory Disorders Unit, Neurology Department, University Hospital Virgen del Rocio, Seville, Spain. Electronic address: aida.gonzalez@ucl.ac.uk. 2. Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, University College London, London, United Kingdom. 3. Department of Radiology, University Hospital Virgen del Rocio, Seville, Spain. 4. Memory Disorders Unit, Neurology Department, University Hospital Virgen del Rocio, Seville, Spain.
Abstract
BACKGROUND: Early and progressive disabling visual impairment is a core feature for the diagnosis of posterior cortical atrophy (PCA). However, some individuals that fulfil criteria over time might initially present with an onset of prominent posterior dysfunction other than visuoperceptual. METHODS: The clinical profile of five patients with a predominantly 'non-visual' posterior presentation (PCA2) was investigated and compared with sixteen individuals with visually predominant PCA (PCA1) and eighteen with typical amnestic Alzheimer disease (tAD). RESULTS: PCA2 patients showed significantly better performance than PCA1 in one visuospatial task and were free of Balint's syndrome and visual agnosia. Compared to tAD, PCA2 showed trends towards significantly lower performance in visuoperceptual tasks, more severe apraxia and more symptoms of Gerstmann's syndrome. CONCLUSIONS: Our sample of PCA2 patients did not present with clinically prominent visual symptoms but did show visual dysfunction on formal neuropsychological assessment (less pronounced than in PCA1 but more than in tAD) in addition to other posterior deficits. Broadening the definition of PCA to encompass individuals presenting with prominent 'non-visual' posterior dysfunction should be potentially considered in clinical and research contexts.
BACKGROUND: Early and progressive disabling visual impairment is a core feature for the diagnosis of posterior cortical atrophy (PCA). However, some individuals that fulfil criteria over time might initially present with an onset of prominent posterior dysfunction other than visuoperceptual. METHODS: The clinical profile of five patients with a predominantly 'non-visual' posterior presentation (PCA2) was investigated and compared with sixteen individuals with visually predominant PCA (PCA1) and eighteen with typical amnestic Alzheimer disease (tAD). RESULTS: PCA2 patients showed significantly better performance than PCA1 in one visuospatial task and were free of Balint's syndrome and visual agnosia. Compared to tAD, PCA2 showed trends towards significantly lower performance in visuoperceptual tasks, more severe apraxia and more symptoms of Gerstmann's syndrome. CONCLUSIONS: Our sample of PCA2 patients did not present with clinically prominent visual symptoms but did show visual dysfunction on formal neuropsychological assessment (less pronounced than in PCA1 but more than in tAD) in addition to other posterior deficits. Broadening the definition of PCA to encompass individuals presenting with prominent 'non-visual' posterior dysfunction should be potentially considered in clinical and research contexts.
Authors: Bruno Dubois; Howard H Feldman; Claudia Jacova; Harald Hampel; José Luis Molinuevo; Kaj Blennow; Steven T DeKosky; Serge Gauthier; Dennis Selkoe; Randall Bateman; Stefano Cappa; Sebastian Crutch; Sebastiaan Engelborghs; Giovanni B Frisoni; Nick C Fox; Douglas Galasko; Marie-Odile Habert; Gregory A Jicha; Agneta Nordberg; Florence Pasquier; Gil Rabinovici; Philippe Robert; Christopher Rowe; Stephen Salloway; Marie Sarazin; Stéphane Epelbaum; Leonardo C de Souza; Bruno Vellas; Pieter J Visser; Lon Schneider; Yaakov Stern; Philip Scheltens; Jeffrey L Cummings Journal: Lancet Neurol Date: 2014-06 Impact factor: 44.182
Authors: S J Ross; N Graham; L Stuart-Green; M Prins; J Xuereb; K Patterson; J R Hodges Journal: J Neurol Neurosurg Psychiatry Date: 1996-10 Impact factor: 10.154
Authors: Manja Lehmann; Sebastian J Crutch; Gerard R Ridgway; Basil H Ridha; Josephine Barnes; Elizabeth K Warrington; Martin N Rossor; Nick C Fox Journal: Neurobiol Aging Date: 2009-09-25 Impact factor: 4.673
Authors: Julie S Snowden; Cheryl L Stopford; Camille L Julien; Jennifer C Thompson; Yvonne Davidson; Linda Gibbons; Antonia Pritchard; Corinne L Lendon; Anna M Richardson; Anoop Varma; David Neary; David Mann Journal: Cortex Date: 2007-10 Impact factor: 4.027
Authors: R C Green; F C Goldstein; S S Mirra; N P Alazraki; J L Baxt; R A Bakay Journal: J Neurol Neurosurg Psychiatry Date: 1995-09 Impact factor: 10.154
Authors: Jonathan M Schott; Basil H Ridha; Sebastian J Crutch; Daniel G Healy; James B Uphill; Elizabeth K Warrington; Martin N Rossor; Nick C Fox Journal: Arch Neurol Date: 2006-01